Taher, A. T., Weatherall, D. J. & Cappellini, M. D. Thalassaemia. Lancet 391, 155–167 (2018).
Google Scholar
Weatherall, D. J. & Clegg, J. B. The Thalassemia Syndrome (Blackwell Scientific, 1981).
Kountouris, P. et al. IthaGenes: an interactive database for haemoglobin variations and epidemiology. PLoS ONE 9, e103020 (2014).
Google Scholar
Orkin, S. & Nathan, D. G. Hematology of Infancy and Childhood (W. B. Saunders, 1998).
Stamatoyannopoulos, G. The Molecular Basis of Blood Diseases (W.B. Saunders, 2001).
Borgna-Pignatti, C. et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89, 1187–1193 (2004).
Google Scholar
Ladis, V. et al. Survival in a large cohort of Greek patients with transfusion-dependent β thalassaemia and mortality ratios compared to the general population. Eur. J. Haematol. 86, 332–338 (2011).
Google Scholar
Mancuso, A., Sciarrino, E., Renda, M. C. & Maggio, A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 30, 119–124 (2006).
Google Scholar
Sadelain, M. et al. Therapeutic options for patients with severe β-thalassemia: the need for globin gene therapy. Hum. Gene Ther. 18, 1–9 (2007).
Google Scholar
Lucarelli, G., Isgro, A., Sodani, P. & Gaziev, J. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb. Perspect. Med. 2, a011825 (2012).
Google Scholar
Baronciani, D. et al. Hematopoietic cell transplantation in thalassemia and sickle cell disease: report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000–2017. Blood 132, 168 (2018).
Fitzhugh, C. D., Abraham, A. & Hsieh, M. M. Alternative donor/unrelated donor transplants for the β-thalassemia and sickle cell disease. Adv. Exp. Med. Biol. 1013, 123–153 (2017).
Google Scholar
Weatherall, D. J. The challenge of haemoglobinopathies in resource-poor countries. Br. J. Haematol. 154, 736–744 (2011).
Google Scholar
Mansilla-Soto, J., Riviere, I., Boulad, F. & Sadelain, M. Cell and gene therapy for the β-thalassemias: advances and prospects. Hum. Gene Ther. 27, 295–304 (2016).
Google Scholar
Ferrari, G., Thrasher, A. J. & Aiuti, A. Gene therapy using haematopoietic stem and progenitor cells. Nat. Rev. Genet. 22, 216–234 (2020).
Magrin, E., Miccio, A. & Cavazzana, M. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies. Blood 134, 1203–1213 (2019).
Google Scholar
Drysdale, C. M. et al. Hematopoietic-stem-cell-targeted gene-addition and gene-editing strategies for β-hemoglobinopathies. Cell Stem Cell 28, 191–208 (2021).
Google Scholar
Persons, D. A. & Tisdale, J. F. Gene therapy for the hemoglobin disorders. Semin. Hematol. 41, 279–286 (2004).
Google Scholar
Sadelain, M. Recent advances in globin gene transfer for the treatment of β-thalassemia and sickle cell anemia. Curr. Opin. Hematol. 13, 142–148 (2006).
Google Scholar
May, C. et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 406, 82–86 (2000).
Google Scholar
May, C., Rivella, S., Chadburn, A. & Sadelain, M. Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene. Blood 99, 1902–1908 (2002).
Google Scholar
Rivella, S., May, C., Chadburn, A., Riviere, I. & Sadelain, M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer. Blood 101, 2932–2939 (2003).
Google Scholar
Lisowski, L. & Sadelain, M. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in β-thalassemic mice. Blood 110, 4175–4178 (2007).
Google Scholar
Perumbeti, A. & Malik, P. Therapy for β-globinopathies: a brief review and determinants for successful and safe correction. Ann. N. Y. Acad. Sci. 1202, 36–44 (2010).
Google Scholar
Quek, L. & Thein, S. L. Molecular therapies in β-thalassaemia. Br. J. Haematol. 136, 353–365 (2007).
Google Scholar
Boulad, F. et al. Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood 123, 1483–1486 (2014).
Google Scholar
Felfly, H. & Trudel, M. Successful correction of murine sickle cell disease with reduced stem cell requirements reinforced by fractionated marrow infusions. Br. J. Haematol. 148, 646–658 (2010).
Google Scholar
Bartelink, I. H. et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 3, e526–e536 (2016).
Google Scholar
Hu, J. et al. Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. Blood 121, 3246–3253 (2013).
Google Scholar
Villa, E. et al. The E3 ligase UBR2 regulates cell death under caspase deficiency via Erk/MAPK pathway. Cell Death Dis. 11, 1041 (2020).
Google Scholar
Berry, C. C., Ocwieja, K. E., Malani, N. & Bushman, F. D. Comparing DNA integration site clusters with scan statistics. Bioinformatics 30, 1493–1500 (2014).
Google Scholar
Yoon, J. K. et al. HIV proviral DNA integration can drive T cell growth ex vivo. Proc. Natl Acad. Sci. USA 117, 32880–32882 (2020).
Google Scholar
Katano, H. et al. Integration of HIV-1 caused STAT3-associated B cell lymphoma in an AIDS patient. Microbes Infect. 9, 1581–1589 (2007).
Google Scholar
Bushman, F. D. Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones. Mol. Ther. 28, 352–356 (2020).
Google Scholar
Thompson, A. A. et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N. Engl. J. Med. 378, 1479–1493 (2018).
Google Scholar
Schneiderman, J. et al. Interim results from the phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) studies of betibeglogene autotemcel gene therapy (LentiGlobin) for the treatment of transfusion-dependent β-thalassemia. Biol. Blood Marrow Transplant. 26, S87–S88 (2020).
Frangoul, H. et al. Safety and efficacy of CTX001 in patients with transfusion-dependent β-thalassemia and sickle cell disease: early results from the Climb THAL-111 and Climb SCD-121 studies of autologous CRISPR–CAS9-modified CD34+ hematopoietic stem and progenitor cells. Blood 136, 3–4 (2020).
Grochow, L. B. et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother. Pharmacol. 25, 55–61 (1989).
Google Scholar
Lawson, R., Staatz, C. E., Fraser, C. J. & Hennig, S. Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients. Clin. Pharmacokinet. 60, 17–51 (2021).
Google Scholar
Strouse, C. et al. Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant. Biol. Blood Marrow Transpl. 24, 2072–2080 (2018).
Marktel, S. et al. Platelet transfusion refractoriness in highly immunized β thalassemia children undergoing stem cell transplantation. Pediatr. Transpl. 14, 393–401 (2010).
Google Scholar
Saito, A. M. et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transpl. 40, 209–217 (2007).
Google Scholar
Svahn, B. M., Alvin, O., Ringden, O., Gardulf, A. & Remberger, M. Costs of allogeneic hematopoietic stem cell transplantation. Transplantation 82, 147–153 (2006).
Google Scholar
La Nasa, G. et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood 122, 2262–2270 (2013).
Google Scholar
Jones, R. J. & DeBaun, M. R. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both or neither. Blood 138, 942–947 (2021).
Hsieh, M. M. et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv. 4, 2058–2063 (2020).
Google Scholar
Li, Y. et al. Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature. Mod. Pathol. 32, 1712–1726 (2019).
Google Scholar
Seminog, O. O., Ogunlaja, O. I., Yeates, D. & Goldacre, M. J. Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study. J. R. Soc. Med. 109, 303–309 (2016).
Google Scholar
Brunson, A. et al. Increased risk of leukemia among sickle cell disease patients in California. Blood 130, 1597–1599 (2017).
Google Scholar
Grimley, M. et al. Early results from a phase 1/2 study of Aru-1801 gene therapy for sickle cell disease (SCD): manufacturing process enhancements improve efficacy of a modified gamma globin lentivirus vector and reduced intensity conditioning transplant. Blood 136, 20–21 (2020).
Scaramuzza, S. et al. Clinical outcomes from a phase I/II gene therapy trial for patients affected by severe transfusion dependent β-thalassemia: two years follow up. Mol. Ther. 28, 169 (2020).
Marktel, S. et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent β-thalassemia. Nat. Med. 25, 234–241 (2019).
Google Scholar
Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467, 318–322 (2010).
Google Scholar
Bank, A., Dorazio, R. & Leboulch, P. A phase I/II clinical trial of β-globin gene therapy for β-thalassemia. Ann. N. Y. Acad. Sci. 1054, 308–316 (2005).
Google Scholar
Ikeda, K., Mason, P. J. & Bessler, M. 3′UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood 117, 5860–5869 (2011).
Google Scholar
Murakami, Y. et al. Deregulated expression of HMGA2 is implicated in clonal expansion of PIGA deficient cells in paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 156, 383–387 (2012).
Google Scholar
Yu, K. R. et al. HMGA2 regulates the in vitro aging and proliferation of human umbilical cord blood-derived stromal cells through the mTOR/p70S6K signaling pathway. Stem Cell Res. 10, 156–165 (2013).
Google Scholar
Bottardi, S., Ross, J., Pierre-Charles, N., Blank, V. & Milot, E. Lineage-specific activators affect β-globin locus chromatin in multipotent hematopoietic progenitors. EMBO J. 25, 3586–3595 (2006).
Google Scholar
Jimenez, G., Griffiths, S. D., Ford, A. M., Greaves, M. F. & Enver, T. Activation of the β-globin locus control region precedes commitment to the erythroid lineage. Proc. Natl Acad. Sci. USA 89, 10618–10622 (1992).
Google Scholar
Schumm, M. et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. J. Hematother. 8, 209–218 (1999).
Google Scholar
Alter, B. P., Rappeport, J. M., Huisman, T. H., Schroeder, W. A. & Nathan, D. G. Fetal erythropoiesis following bone marrow transplantation. Blood 48, 843–853 (1976).
Google Scholar
Yang, S. et al. A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes. Hum. Gene Ther. Methods 23, 73–83 (2012).
Google Scholar
Charrier, S. et al. Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction. Gene Ther. 18, 479–487 (2011).
Google Scholar
Shear, H. L. et al. Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism. Blood 92, 2520–2526 (1998).
Google Scholar
Berry, C. C. et al. INSPIIRED: quantification and visualization tools for analyzing integration site distributions. Mol. Ther. Methods Clin. Dev. 4, 17–26 (2017).
Google Scholar
Sherman, E. et al. INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes. Mol. Ther. Methods Clin. Dev. 4, 39–49 (2017).
Google Scholar
Berry, C. C. et al. Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics 28, 755–762 (2012).
Google Scholar
